Clin Gastroenterol Hepatol by McMahon, Brian J et al.
Infection With Hepatitis C Virus Genotype 3 is an Independent 
Risk Factor for End-stage Liver Disease, Hepatocellular 
Carcinoma, and Liver-related Death
Brian J McMahon1,2, Dana Bruden2, Lisa Townshend-Bulson1, Brenna Simons1, Phillip 
Spradling3, Stephen Livingston1, James Gove1, Annette Hewitt1, Julia Plotnik1, Chriss 
Homan1, Hannah Espera1, Susan Negus1, Mary Snowball1, Youssef Barbour1, Michael 
Bruce2, and Prabhu Gounder2
1Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium
2Arctic Investigations Program, Division of Preparedness and Emerging Infections, National 
Center for Emerging and Zoonotic Infectious Diseases, CDC, Anchorage, Alaska
3Division of Viral Hepatitis, Centers for HIV, TB, STD and Viral Hepatitis, CDC, Atlanta, Georgia
Abstract
Background & Aims—Few studies have examined factors associated with disease progression 
in hepatitis C virus (HCV) infection. We examined the association of 11 risk factors with adverse 
outcomes in a population-based prospective cohort observational study of Alaska Native/American 
Indian persons with chronic HCV infection.
Methods—We collected data from a population-based cohort study of liver-related adverse 
outcomes of infection in American Indian/Alaska Native persons with chronic HCV living in 
Alaska, recruited from 1995 through 2012. We calculated adjusted hazard ratios (aHR) and 95% 
CIs for end-stage liver disease (ESLD; presence of ascites, esophageal varices, hepatic 
encephalopathy, or coagulopathy), hepatocellular carcinoma (HCC), and liver-related death using 
a Cox proportional hazards model.
Results—We enrolled 1080 participants followed for 11,171 person-years (mean, 10.3 years); 
66%, 19%, and 14% were infected with HCV genotypes 1, 2, and 3, respectively. On multivariate 
analysis, persons infected with HCV genotype 3 had a significantly increased risk of developing 
Corresponding Author: Brian J McMahon Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium 4315 
Diplomacy Drive, Anchorage, AK 99508, Phone 907-729-3419, Fax 907-729-3429, bdm9@cdc.gov. 
The findings and conclusions in this article are those of the authors and do not necessarily represent the official positions of the U.S. 
Centers for Disease Control and Prevention.
Contribution of Authors: (1) Conception and design of the study: BJM, DB, LT; (2) Generation, collection, assembly, analysis and/or 
preparation of data: BJM. DB, LT, SL, JG, JP, AH, CH, HE, SN, MS, YB. (3) Drafting or revision of the manuscript: BJM. DB, LT, 
BS, PS, MB, PG. (4) Approval of the final version of the manuscript: All authors
CONFLICT OF INTEREST STATEMENT: LT-B, BS-P and YB have received research support from Gilead Sciences. The other 
authors do not have a commercial or other association that might pose a conflict of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2018 March 01.
Published in final edited form as:













all 3 adverse outcomes. Their aHR for ESLD was 2.1 (95% CI, 1.5–3.0), aHR for HCC was 3.1 
(95% CI, 1.4–6.6), and aHR for liver-related death was 2.4 (95% CI, 1.5–4.0) compared to 
genotype 1. Heavy alcohol use was an age-adjusted risk factor for ESLD (aHR, 2.2; 95% CI, 1.6–
3.2), and liver-related death (aHR: 2.9; 95% CI, 1.8–4.6). Obesity was a risk factor for ESLD 
(aHR, 1.4; 95% CI, 1.0–1.9, and diabetes was a risk factor for ESLD (aHR, 1.5; 95% CI, 1.1–2.2). 
Male sex was a risk factor for HCC (aHR, 3.6; 95% CI, 1.6–8.2).
Conclusions—In a population-based cohort study of American Indian/Alaska Native persons 
with chronic HCV infection, we found those infected with HCV genotype 3 to be at high risk for 
ESLD, HCC, and liver-related death.
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Hepatitis C Outcome; AK-HEPC; liver cancer risk; American Indian/ Alaska Native
Introduction
Infection from Chronic hepatitis C virus (HCV) is a significant cause of cirrhosis, 
hepatocellular carcinoma and liver related death worldwide, with an estimated 140 to 170 
million persons infected. (1) In the United States (US), an estimated 2% to 3% of persons 
born between 1945 and 1965 have chronic hepatitis C with 2 to 3 million persons infected.
(2) Due to the paucity of large population-based prospective cohort studies of persons with 
chronic hepatitis C, the factors associated with progression of disease such as viral genotype, 
viral load, mode of acquisition of infection and previous exposure to hepatitis B virus to 
mention a few, are not well elucidated. Since 1995, the Alaska Native Tribal Health 
Consortium (ANTHC), Liver Disease and Hepatitis Program (LDHP) in collaboration with 
the Arctic Investigations Program and the Division of Viral Hepatitis of the Centers for 
Disease Control and Prevention (CDC) have been conducting a population-based cohort 
study (AKHEPC) of liver related adverse outcomes of chronic HCV infection in American 
Indian/Alaska Native (AI/AN) persons residing in Alaska. We previously determined that 
the AK-HepC cohort had similar risk factors for acquisition and HCV genotype distribution 
when compared to the National Health and Nutritional Examination Survey (NHANES) 
conducted in 1994 of infected persons from the general US population.(3, 4) Previously we 
analyzed outcome both prospectively and retrospectively through 2006 in this cohort and 
compared them to persons who recovered from HCV who were recruited at the same time. 
We found that end stage liver disease (ESLD) was associated with older age and alcohol 
usage. We also found that compared with HCV genotype 2, genotype 3 infection was 
associated with a higher risk of ESLD on multivariate analysis, but not compared with 
genotype 1.(5) For this analysis, we included all persons recruited from 1995–2012 and only 
included data obtained prospectively starting from the time of consent. We examined 11 risk 
factors for any association with ESLD, HCC and liver related death. Herein, we present the 
results of this study.
Methods
ANTHC coordinates ATHS healthcare throughout the state of Alaska. Further details of the 
population and health care delivery system have been described previously and in the 
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supplemental Text.(4) Electronic Health (EHR) records are used in these statewide Tribal 
facilities. Testing for anti-HCV was conducted at the laboratory at the Alaska Native 
Medical Center (ANMC); all positive results were automatically reflexed for HCV RNA 
testing then downloaded into our HCV computerized Registry. All patients in the HCV 
registry, whether they are participants in the study or not, are mailed a letter every six 
months reminding them to go to their local clinic to get tested for liver function tests. A list 
of patients in their area with chronic HCV are sent to each regional facility and updated 
twice yearly. Testing for anti-HCV is conducted at the laboratory at ANMC and all positive 
results are automatically reflexed for HCV RNA testing then downloaded into the HCV 
Registry. The HCV registry includes extensive laboratory data, clinical data and 
demographic data and is used primarily for management of infected persons. All pertinent 
laboratory tests performed at ANMC on patients in the HCV registry are automatically 
downloaded into the AK-HepC database twice weekly. Laboratory data performed at the 
regional hospitals and clinics are added into the data base at the time of field clinic visits and 
by access given to our program to these facilities Electronic Health Records systems. The 
LDHP works with Tribal providers throughout Alaska and conducts field hepatology clinics 
at all regional hospitals once or twice a year. We use telemedicine, Vidyo® clinics, tele-
radiography and other means to care for HCV-infected patients. Since the beginning of this 
study, all patients who are eligible have been offered FDA-approved drugs for treatment at 
the time based on guidelines from the American Association for the Study of Liver Diseases/
Infectious Disease Society of America (AASLD/IDSA).(6) During the period when 
interferon-based therapies were the only licensed regimens available, over 50% of patients 
were deemed eligible candidates for treatment, but most refused.(7) However, in the era of 
direct acting antiviral agents (DAA) licensed in the US since the fall of 2014, almost all 
eligible patients now agree to therapy and are currently offered DAA regardless of stage of 
liver fibrosis. All patients in the registry who were both anti-HCV positive and HCV RNA 
positive for at least one year have been invited to join the AK-HepC study. The study was 
approved by the Alaska Area and CDC Investigational Review Boards. The study was also 
approved by all regional tribal health organization boards in Alaska. All participants 
provided written informed consent.
At the time of AK-HepC study enrollment, study nurses conducted an extensive interview of 
each participant to obtain information on risk factors and demographic data that are 
reviewed in our previous publication.(5) Information was obtained directly from the HCV 
registry, by chart review including ICD9 liver related diagnosis and review of the State of 
Alaska Death Tapes from 1995 through 2012. In addition, an extensive chart review was 
performed on each participant at the end of the study period to examine for clinical evidence 
of liver disease that occurred during the study period. We defined advanced fibrosis as either 
a Knodell fibrosis score ≥3, equivalent to Metavir fibrosis of F3/F4, on liver biopsy or APRI 
≥1.5 which has a specificity of approximately 90%.(8) ESLD was defined by the presence of 
one or more of the following: ascites, esophageal varices, hepatic encephalopathy, or 
coagulopathy (INR ≥1.2 or platelet count <130,000 on at least two occasions more than 2 
months apart). The diagnosis of HCC was made by pathological confirmation or on 
radiographic imaging exam (CT, US or MRI) consistent with a mass lesion with typical 
features for HCC including enhancing during the arterial phase. Liver related death was 
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defined as death with immediate cause from a complication of liver disease or death with 
liver disease listed as a contributing cause in medical chart review and death certificate and 
also included persons who underwent liver transplant. We evaluated the cohort for eleven 
different potential contributing factors that might be associated with each of the four adverse 
outcomes. These included age at start of enrollment, gender, residence (urban or rural), risk 
factor for acquisition of HCV (blood transfusion prior to 1992, injecting drug use or other), 
HCV genotypes 1, 2 and 3, presence of hepatitis B core antibody (anti-HBc) in the absence 
of hepatitis B surface antigen (HBsAg), heavy alcohol consumption (defined as > 50 grams 
average/day at enrollment), tobacco smoker, obesity as defined by a BMI > 30, Type II 
diabetes, and HCV RNA level. HCV RNA level was divided into five categories: < 50,000, 
50,000 to <200,000, 200,000 to <1 million, 1 million to < 5 million, and > 5 million IU/ml. 
Due to the few persons in the AK-HepC cohort with active hepatitis B or HIV infection, 
persons with these co-infections were excluded from analysis.
Laboratory Testing
Detection of anti-HCV antibodies (EIA2.0 [Abbott Laboratories]), and HCV RNA 
(COBAS®Taqman®HCV Test, v2.0 [Roche Molecular Diagnostics]), were performed at the 
Alaska Native Medical Center laboratory (Anchorage, Alaska). HCV viral genotype was 
determined by real-time polymerase chain reaction by Quest Diagnostics (Hepatitis C 
Genotype, LIPA®).
Statistical Analysis
The starting point for all survival analyses was the date of the confirmatory HCV testing. 
Age was calculated at the start of clinical follow-up and divided into quartiles (< 30 years, 
30–39, 40–49, and ≥ 50 years). For risk factors we divided the cohort into persons with a 
pre-1993 blood transfusion (BT), persons with a history of intravenous drug use (IVDU) and 
all others. Persons living in Anchorage, Juneau, Fairbanks and surrounding areas were 
considered urban residents with all others classified as rural. For persons treated for HCV, 
the end of follow-up was defined as the treatment start date. The end of follow-up among 
those with an outcome was the date of detection of ESLD, HCC, liver related death (primary 
outcomes) or advanced fibrosis (secondary outcome). Among those without an outcome, the 
date of their last clinical follow-up or their date of death was used. For ESLD, the date of 
their first ESLD objective finding was used. We used the Cox-Proportional hazards model to 
report uni-variable and multi-variable p-values. We used a purposeful forward selection 
method to build a final multi-variable model. Factors with a uni-variable p-value < 0.25 were 
considered in the building of the multi-variable models. Variables were considered 
confounders and remained in the model if their exclusion changed the value of the 
coefficients of interest by more than 15%. All reported p-values are two-sided, were not 
adjusted for multiple testing, and a value < 0.05 was considered statistically significant. 
Kaplan-Meier survival estimates were used to report the probabilities of the outcome after 
15 years of follow-up.
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Among 1,132 persons found to have chronic HCV through 2012, 1080 (95.4%) were 
enrolled. Table 1 gives the demographic, risk factors, clinical, social and laboratory 
characteristics of this cohort. Two thirds of participants (66%) were infected with HCV 
genotype 1, 90% with 1a, while 19% and 14% were infected with HCV genotype 2, and 3, 
respectively. At study entry, 22% of genotype 3 patients had an elevated APRI score (≥ 1.5) 
which did not differ from 21% and 23% in genotype 1 and 2 patients, respectively. The 1080 
persons were followed prospectively for 11,171 person years (mean of 10.3 years). The 
median age at the time of enrollment was 41 years and 51% of participants were female. 
HIV co-infection was found in 29 and HBsAg in 10; as mentioned in the Methods, these 
patients are not included in the outcome analysis. A total of 157 patients received interferon-
based antiviral treatment, of which 76 achieved SVR and were censored from further 
analysis after that time. Over half of the patients were tobacco smokers and 10% had 
diabetes. Daily heavy alcohol intake was reported by 14% of participants. Over half of the 
patients lived in cities with a population above 10,000 (urban).
During the study period, 341 persons developed advanced fibrosis, 210 ESLD, 40 HCC and 
96 liver related death, with some patients developing more than one of these adverse 
outcomes. Of the 341 patients with advanced fibrosis, 190 (56%) were identified by liver 
biopsy, and 151 (44%) were identified by their APRI scores. Of the 40 patients with HCC, 
39 met the definition of HCC we used in the methods. One patient with 4 cm lesion of the 
liver on US, liver failure, history of stroke and multiple contractures could not fit 
comfortably into the CT or MRI scanners. He developed a second lesion several months 
later and died of liver failure. We included him as a probable case of HCC.
Table 2 shows the results of Hazard Ratios (HRs) in univariate analysis for the 11 risk 
factors for all three primary outcomes. Using HCV genotype 1 as the referent, persons 
infected with genotype 3 were significantly more likely to develop ESLD and liver related 
death and those with genotype 2 were less likely to develop ESLD. Developing ESLD was 
significantly associated with age at start of follow-up, HCV genotype 3, heavy alcohol 
usage, and type II diabetes. HCC was associated with male sex and age at start of follow-up. 
Liver related death was associated with age, genotype 3, presence of Hep B Core antibody, 
DM2 and heavy alcohol usage. Results for the secondary outcome of advanced fibrosis were 
very similar to the results for ESLD and are included in supplemental Tables 1 and 2.
The multi-variable model for ESLD identified for HCV genotype (1, 2, and 3), age at cohort 
entry, heavy alcohol use (average >50 grams/day), obesity (body mass index [BMI] ≥30), 
and type II diabetes (DM2) (Table 3) as factors significantly associated with risk of ESLD. 
The model for HCC identified HCV genotype, age at cohort entry, and sex as risk factors. 
HCV genotype, age at cohort entry, and heavy alcohol use were significant factors 
associated with liver related death. Persons infected with HCV genotype 3 were significantly 
more likely to develop all three adverse outcomes, ESLD, HCC and liver related death than 
those infected with HCV genotype 1. After 15 years of clinical follow-up, the probability of 
developing ESLD for those infected with HCV genotype 3 was 48% and for liver related 
death was 24%. Older age at enrollment was also associated with all three adverse outcomes. 
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The increases in risk for developing ESLD were heavy alcohol use (aHR: 2.2; CI: 1.6–3.2), 
obesity (aHR: 1.4; CI: 1.0–1.9; p = 0.03), and DM2 (aHR: 1.5; CI: 1.0–2.3; p = 0.03). The 
risk for developing HCC was higher for males than females (aHR: 3.6; CI: 1.6–8.2). Persons 
with heavy alcohol use were at increased risk for liver related death (aHR: 2.9; CI: 1.8–4.6) 
(Table 3). Several important risk factors were not associated with any of the adverse 
outcomes on multi-variable analysis. Surprisingly, HCV RNA level had no effect on any of 
the outcomes. The risk factor for acquisition also did not have any effect, nor did the 
presence of anti-HBc in the absence of HBsAg, which could indicate occult HBV.
Discussion
To our knowledge, the AK-HEPC study is the largest and longest population-based cohort 
study to examine the long-term outcome of chronic HCV infection. This population-based 
study of over 1,000 participants (94% of the known Alaska Native Persons with chronic 
HCV infection in the state), followed for 11,171 person years, a mean of over 10 years, was 
designed to prospectively examine adverse events due to HCV infection. The study 
encompasses a large amount of clinical and laboratory data coupled with baseline risk factor, 
electronic medical records, State of Alaska death records and other data collected at entry 
plus personal clinical statewide follow-up by the providers and nurses on our LDHP team. 
We found an important association with the adverse outcomes of ESLD, HCC and liver 
related death in those infected with HCV genotype 3 compared to genotype 1. In the AK-
HEPC cohort 14% have genotype 3. In this cohort, within 15 years of diagnosis, two-thirds 
of those with genotype 3 had progressed to advanced fibrosis, half to ESLD, one quarter had 
died or had received a liver transplant and almost 1 in 10 developed HCC.
Recently, a retrospective study in the VA using a search of their HCV Clinical Registry and 
ICD9 codes, found that HCV genotype 3 was associated with a 31% higher risk of 
developing cirrhosis and 80% higher risk of developing HCC compared with genotype 1 
patients.(9) to the authors and our knowledge, the VA study was the first to show that HCV 
genotype 3 had a higher risk of cirrhosis and HCC than genotype 1. We confirm their 
findings of an increased risk of HCC and ESLD and extend this significant risk to include 
advanced fibrosis and liver related death. In their discussion, the authors commented on the 
limitation of their study as it was retrospective in nature and that a large prospective cohort 
study with sufficient follow-up was unlikely to be conducted due to cost and feasibility. 
However, we actually have conducted such a study as reported herein. The VA study relied 
on ICD9 codes whereas we actively followed participants prospectively. One third of the 
patients in the VA Clinical Registry did not have HCV genotype testing done, as opposed to 
only 4 of 1,080 persons in our study, and the VA study did not eliminate persons with HIV 
or HBV co-infection, plus included patients who were previously treated for HCV. Genotype 
3 may excerpt some of its adverse effects by increasing liver steatosis independent of 
diabetes or obesity resulting in more rapid liver fibrosis which then leads to higher rates of 
cirrhosis and HCC.(10) In a previous study looking at factors associated with the amount of 
fibrosis on liver biopsy, we found that steatosis was prominent in those with genotype 3 and 
an independent risk factor. Fibrosis and steatosis were more advanced in genotype 3 patients 
compared to genotypes 1 and 2 when adjustment for BMI and diabetes was performed.(11) 
As seen in Table 2, there were no differences in adverse outcomes between urban and rural 
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areas or differences in the distribution of the important risk factors of HCV genotype, 
obesity, risk exposure, or alcohol use.
Surprisingly, we found that HCV RNA level was not associated with any of the outcomes in 
multi-variable analysis. In performing this analyses, we divided participants into five groups 
based on their initial HCV RNA level, ranging from <50,000 to > 5 million IU/ml, with well 
over 100 participants in each group. This was in contrast to what has been found in studies 
of chronic hepatitis B virus (HBV) infection, our long-term prospective chronic hepatitis B 
outcome study in AN/AI persons, where higher levels of HBV DNA, especially above 
20,000 IU/ml, are a significant risk factor in developing HCC and cirrhosis.(12–14). It is not 
clear why viral level in HCV was not found to be associated with outcome. It is possible that 
the vigorous immune response evoked by the presence of HCV, regardless of viral level, is 
the critical factor in promoting progression, rather than the activity of the virus itself. We 
also found that HCV infected persons with occult HBV infection, those negative for HBsAg 
but positive for anti-HBc, had no greater risk of developing any of the adverse outcomes.
There are a few limitations to our study. First of all, all participants are AI/AN persons, but, 
since the characteristics in the AK-HepC cohort did not differ from those found in the 
NHANES study of the general US population with regards to prevalence, distribution of risk 
factors and prevalence of HCV genotypes,(4) it is less likely that significant differences in 
risk factors for disease outcome are present. In addition, response to interferon-based 
therapy are similar to previous US studies and registration trials.(15)
In conclusion, our study has yielded some important findings regarding the risk factors for 
progression of HCV to adverse life threatening outcomes. The most striking finding was that 
HCV genotype 3 has significant risk for the development of all adverse outcomes studied, 
suggesting that persons with genotype 3 HCV infection should be prioritized for treatment. 
However, currently genotype 3 is the most difficult HCV genotype to treat, especially for 
patients with cirrhosis or who were previously treated and failed to achieve SVR. 
Fortunately, new pan-genotype oral antivirals are on the horizon and could be available soon, 
offering the opportunity to better target patients with HCV genotype 3.
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Table 1
Characteristics of persons chronically infected with the hepatitis C virus amongst American Indian/Alaska 
Native (AI/AN) persons (AK-Hep C cohort, Alaska, 1995–2012).
Characteristic Level N (%) or Median (IQR) PCR Positive (n = 1081)



















HCV RNA level at Start of Clinical Follow-up b (IU/ml)
<50,000 177 (17%)
50,000 – <200,000 202 (19%)
≥200,000 – < 1 Mil 276 (26%)
≥1 Mil – < 5 Mil 286 (27%)
≥5 Mil 127 (12%)
Known HIV Coinfection 29 (3%)








Intravenous Drug Use 614 (57%)
Pre-1992 Blood Transfusion 122 (11%)
Other 345 (32%)
Treated for HCV Infection
Yes 157 (15%)
No 923 (85%)
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Characteristic Level N (%) or Median (IQR) PCR Positive (n = 1081)
Daily ETOH c
Heavy (> 50 gm/day) 147 (14%)
Moderate (30–50 gm/day) 164 (15%)




No 534 (49%)534 (49%)
Known Type II Diabetes
Yes 109 (10%)
No 972 (90%)




4 persons positive for HCV RNA are missing an HCV genotype.
b
13 people positive for HCV RNA were missing an RNA level, positive result only reported.
c
10 persons are missing alcohol use.
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